Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity

Autor: Mirkka Sarparanta, Surachet Imlimthan, Iris Katariina Sokka, Filip S. Ekholm, Mikael P. Johansson, Hannu Maaheimo

Publikováno v: Sokka, I K, Imlimthan, S, Sarparanta, M, Maaheimo, H, Johansson, M P & Ekholm, F S 2021, ' Halogenation at the phenylalanine residue of monomethyl auristatin f leads to a favorable cis/ trans equilibrium and retained cytotoxicity ', Molecular Pharmaceutics, vol. 18, no. 8, pp. 3125-3131 . https://doi.org/10.1021/acs.molpharmaceut.1c00342
Molecular Pharmaceutics

Halogenation can be utilized for the purposes of labeling and molecular imaging, providing a means to, e.g., follow drug distribution in an organism through positron emission tomography (PET) or study the molecular recognition events unfolding by nuc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95f58ef077c9074a6334b247722d50d
https://doi.org/10.1021/acs.molpharmaceut.1c00342

Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and In Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates

Autor: Jan-Erik Raitanen, Mikael P. Johansson, Juulia Järvinen, Jarkko Rautio, Surachet Imlimthan, Hannu Maaheimo, Anu J. Airaksinen, Sirpa Peräniemi, Jelena Matovic, Ahmed Montaser, Iris Katariina Sokka, Mirkka Sarparanta, Kristiina M. Huttunen, Filip S. Ekholm

Publikováno v: Matović, J, Järvinen, J, Sokka, I K, Imlimthan, S, Raitanen, J E, Montaser, A, Maaheimo, H, Huttunen, K M, Peräniemi, S, Airaksinen, A J, Sarparanta, M, Johansson, M P, Rautio, J & Ekholm, F S 2021, ' Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT : Chemical Synthesis and in Vitro Evaluation of the Entire Positional Isomer Library of ortho-Carboranylmethyl-Bearing Glucoconjugates ', Molecular Pharmaceutics, vol. 18, no. 1, pp. 285-304 . https://doi.org/10.1021/acs.molpharmaceut.0c00917

Boron neutron capture therapy (BNCT) is a noninvasive binary therapeutic modality applicable to the treatment of cancers. While BNCT offers a tumor-targeting selectivity that is difficult to match by other means, the last obstacles preventing the ful

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d4ebd61d3f900e8c6d0656aebc158ac
http://hdl.handle.net/10138/340053